

Eskata[™] (hydrogen peroxide) – New drug approval

- On December 15, 2017, <u>Aclaris Therapeutics announced</u> the <u>FDA approval</u> of <u>Eskata (hydrogen peroxide)</u> for the treatment of seborrheic keratoses (SK) that are raised.
- SKs are non-cancerous skin growths affecting more than 83 million Americans. SKs are often
 elevated, waxy, or scaly in appearance and vary in color and size, from a millimeter to a few
 centimeters in width.
- The approval of Eskata was based on two vehicle-controlled trials involving 937 patients with 4 clinically typical SK lesions. In these trials, patients received up to 2 treatments with Eskata. The primary endpoint was the proportion of subjects that became clear of their lesions by day 106.
 - Across both trials, more patients treated with Eskata became clear of all 4 lesions vs. vehicle (4% 8% vs. 0%).
 - In addition, more Eskata-treated patients were clear in at least 3 out of 4 lesions vs. vehicle (13% – 23% vs. 0%).
- Warnings and precautions of Eskata include eye disorders and local skin reactions.
- Common adverse reactions with Eskata use were erythema (99%), stinging (97%), edema (91%), scaling (90%), crusting (81%), and pruritus (58%).
- During a single in-office treatment session, Eskata should be applied to SK lesions four times, approximately 1 minute apart. After one use, the unit dose applicator should be discarded.
 - If the treated lesions have not completely cleared approximately 3 weeks after treatment, another treatment may be administered following the same procedure.
 - Eskata is to be administered by a health care provider and for topical use only. It is not for oral, ophthalmic, or intravaginal use.
 - Eskata should not be applied to open or infected SK.
- Aclaris Therapeutics plans to launch Eskata in the spring of 2018. Eskata will be available as a 40% (w/w) topical solution in a unit dose package.



optumrx.com

OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at **optum.com**.

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.